Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial
Silo Pharma (NASDAQ: SILO) has received a Notice of Allowance from the USPTO for patent application 17/954,864, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.' This patent, expected to be formally issued within 90 days, will strengthen protection for SPC-15, the company's lead asset targeting post-traumatic stress disorder (PTSD) through intranasal delivery.
The patent includes new claims to U.S. Patent 11,491,120, which was issued to Silo in February 2023. The company holds an exclusive license agreement with Columbia University for global development, manufacturing, and commercialization rights of SPC-15, including extensive issued patents and pending IP patent applications.
Silo Pharma (NASDAQ: SILO) ha ricevuto un Avviso di Concessione dalla USPTO per la domanda di brevetto 17/954,864, intitolata 'Prophylattici Farmacologici contro i Disturbi Affettivi Indotti dallo Stress nelle Donne.' Questo brevetto, che si prevede sarà formalmente emesso entro 90 giorni, rafforzerà la protezione per SPC-15, il principale asset dell'azienda che mira a trattare il disturbo da stress post-traumatico (PTSD) tramite somministrazione intranasale.
Il brevetto include nuove rivendicazioni relative al Brevetto Statunitense 11,491,120, rilasciato a Silo nel febbraio 2023. L'azienda detiene un accordo di licenza esclusiva con la Columbia University per lo sviluppo globale, la produzione e i diritti di commercializzazione di SPC-15, compresi numerosi brevetti emessi e domande di brevetto IP in sospeso.
Silo Pharma (NASDAQ: SILO) ha recibido un Aviso de Aprobación de la USPTO para la solicitud de patente 17/954,864, titulada 'Profilácticos Farmacológicos Contra los Trastornos Afectivos Inducidos por Estrés en Mujeres.' Esta patente, que se espera que sea emitida formalmente dentro de 90 días, fortalecerá la protección de SPC-15, el principal activo de la empresa enfocado en tratar el trastorno de estrés postraumático (PTSD) a través de la administración intranasal.
La patente incluye nuevas reclamaciones relacionadas con la Patente de EE. UU. 11,491,120, que fue otorgada a Silo en febrero de 2023. La empresa tiene un acuerdo de licencia exclusivo con la Universidad de Columbia para el desarrollo global, la fabricación y los derechos de comercialización de SPC-15, incluyendo extensas patentes emitidas y solicitudes de patente IP pendientes.
시로파마(SILO Pharma, NASDAQ: SILO)는 '여성의 스트레스 유발 정서 장애에 대한 약리학적 예방조치'라는 제목의 특허 출원 17/954,864에 대해 USPTO에서 허가 통지를 받았습니다. 이 특허는 90일 이내에 정식으로 발급될 것으로 예상되며, SPC-15에 대한 보호를 강화할 것입니다. SPC-15는 회사의 주요 자산으로 외상 후 스트레스 장애(PTSD)를 비강 투여 방식으로 치료하는 데 초점을 맞추고 있습니다.
이 특허는 2023년 2월에 시로에게 발급된 미국 특허 11,491,120에 대한 새로운 청구를 포함합니다. 이 회사는 SPC-15의 세계적 개발, 제조 및 상용화 권리에 대해 컬럼비아 대학교와 독점 라이선스 계약을 체결하고 있으며, 광범위하게 발급된 특허와 대기 중인 지적 재산권 특허 신청서를 보유하고 있습니다.
Silo Pharma (NASDAQ: SILO) a reçu un Avis d'Acceptation de l'USPTO pour la demande de brevet 17/954,864, intitulée 'Prophylaxies Pharmacologiques Contre les Troubles Affectifs Induits par le Stress chez les Femmes.' Ce brevet, qui devrait être officiellement délivré dans un délai de 90 jours, renforcera la protection du SPC-15, l'actif principal de l'entreprise ciblant le trouble de stress post-traumatique (TSPT) par voie intranasale.
Le brevet comprend de nouvelles revendications concernant le Brevet Américain 11,491,120, qui a été délivré à Silo en février 2023. L'entreprise détient un accord de licence exclusif avec l'Université de Columbia pour le développement mondial, la fabrication et les droits de commercialisation de SPC-15, y compris de nombreux brevets délivrés et des demandes de brevets IP en attente.
Silo Pharma (NASDAQ: SILO) hat eine Genehmigungsmitteilung vom USPTO für die Patentanmeldung 17/954,864 erhalten, die den Titel 'Pharmazeutische Prophylaktika gegen stressinduzierte affektive Störungen bei Frauen' trägt. Dieses Patent, das voraussichtlich innerhalb von 90 Tagen offiziell erteilt wird, wird den Schutz für SPC-15, das Hauptprodukt des Unternehmens, das auf Posttraumatische Belastungsstörung (PTBS) abzielt und intranasal verabreicht wird, stärken.
Das Patent umfasst neue Ansprüche zu dem US-Patent 11.491.120, das im Februar 2023 an Silo erteilt wurde. Das Unternehmen hat einen exklusiven Lizenzvertrag mit der Columbia University für die globale Entwicklung, Herstellung und Vermarktungsrechte von SPC-15, einschließlich umfangreicher erteilter Patente und ausstehender IP-Patentanmeldungen.
- Receipt of USPTO Notice of Allowance for new patent application
- Expected patent issuance within 90 days strengthening SPC-15 protection
- Exclusive global license agreement with Columbia University for SPC-15
- Company still in developmental stage with no commercialized products
Insights
This patent allowance significantly strengthens Silo Pharma's intellectual property position for SPC-15. The Notice of Allowance from USPTO essentially guarantees patent issuance, providing 20 years of market exclusivity from the filing date. The expanded claims beyond the original US Patent 11,491,120 specifically addressing female PTSD patients represent a strategic expansion of IP protection. The exclusive global license agreement with Columbia University adds another layer of commercialization rights and barriers to entry for competitors.
For investors, patent protection is important in the biopharmaceutical sector as it directly impacts potential market share and revenue streams. The gender-specific claims could allow Silo to target a significant yet underserved demographic in PTSD treatment. The Columbia University backing adds institutional credibility and access to additional research resources.
The development of SPC-15 as an intranasal PTSD treatment represents a novel drug delivery approach in a market with significant unmet needs. The global PTSD therapeutics market is projected to reach
In simple terms, think of this like having an exclusive recipe for a new type of medicine that can be sprayed into the nose instead of taken as pills, potentially working better and faster. The patent specifically for female patients is important because women are twice as likely to develop PTSD than men, yet most existing treatments weren't specifically designed for them.
SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” Following receipt of the Notice of Allowance, Silo filed the final issue paperwork, paid the issue fees, and expects formal issuance of the patent in the next 90 days
The patent, when formally approved, will reinforce protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in February 2023.
“We are pleased to kick off 2025 with this expected addition to our intellectual property portfolio. The approval of this patent broadens protection for SPC-15 and expands our technology rights,” said Eric Weisblum, CEO of Silo.
Silo holds an exclusive license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally. Through the agreement, Silo acquired extensive issued patents and pending IP patent applications for SPC-15 technology.
About SPC-15
SPC-15 is a serotonin 5-HT4 receptor agonist designed to treat stress-induced disorders such as PTSD and anxiety. Delivered via an intranasal formulation, SPC-15 may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, potentially accelerating its approval process. Currently, Silo Pharma is collaborating with Columbia University on preclinical studies and holds exclusive rights to develop and commercialize SPC-15 globally.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information, visit www.silopharma.com and connect on social media at LinkedIn , X , and Facebook .
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the new patent Silo Pharma (SILO) received approval for in January 2025?
When will Silo Pharma's new patent for SPC-15 be formally issued?
What is Silo Pharma's relationship with Columbia University regarding SPC-15?
What medical condition does Silo Pharma's SPC-15 target?
